Skip to the main content.
Facebook Linkedin X

Peptide Mapping by MS MoM-1

Reduce Risk in Drug Development  

Learn how peptide mapping by mass spectrometry provides amino acid-level insight into your biotherapeutic, enabling structural confirmation, impurity identification, and regulatory-ready characterization. Practical insights from Ben Zigterman, Senior Scientist in Characterization Services at KBI Biopharma. 

Get the Full Video and Guide

Why Peptide Mapping Matters   

Structure is function. When something goes wrong with a biotherapeutic, whether it is unexpected potency loss, an unfamiliar impurity, or a signal from a lot release assay that no one can explain, understanding the primary structure at the amino acid level is often critical to diagnosing the root cause. Without peptide mapping, development teams risk missing structural problems that other analytical methods simply cannot see. 

Early Impurity Detection

Catch what standard platform assays miss

Regulatory-Ready Characterization

Build packages that meet FDA and EMA expectations at filing

Root Cause Diagnosis

 Pinpoint exactly what changed and why

Lower Remediation Costs

Fix structural problems early when changes cost thousands, not millions 

What You’ll Learn: 

  • What peptide mapping is, when to use it, and why it is effectively compulsory for IND and BLA submissions
  • Real-world case study: How KBI identified a gene-splicing error that standard assays could detect but not diagnose
  • The most common design mistake and how to avoid

Dive Deeper Into the Case Study

In this episode, Ben discusses how KBI's team tracked down an unexpected mAb variant that affected 20-30% of total product. Standard product quality methods, including cIEF, SEC, and a peptide mapping identity method, all provided no insight. KBI developed a customized top-down LC-MS strategy that identified the variant as a C-terminal extension caused by an aberrant gene-splicing event, enabling the customer to remediate their process and continue program development.

Read the full case study: Tracking mAb Variant with Customized LC-MS Strategy | KBI Biopharma

Watch the poster presentation: Poster | LC-MS characterization of an unexpected C-terminal HC extension in a Therapeutic mAb

Access Both Formats Today! 

Fill out the form above to get instant access to both the full video interview and the comprehensive guide with Ben Zigterman, Senior Scientist in Characterization Services at KBI Biopharma.

Full Video Interview

35-minute comprehensive conversation 
  • Complete interview with Ben Zigterman
  • Real-world case studies and examples
  • In-depth discussion of PTM profiling, investigational workflows, and study design strategy 

Interactive Guide 

Comprehensive guide with video clips 
  • Comprehensive written resource
  • Key video clips embedded throughout
  • Easy to reference and share

GET THE VIDEO AND GUIDE

Ben Zigterman headshot

 

MEET YOUR EXPERT: Ben Zigterman

Senior Scientist, Characterization Services 
KBI Biopharma, Louisville, Colorado

Ben joined KBI Biopharma in 2015 and holds a Bachelor of Science in Chemistry from Colorado State University. With 14 years of experience in protein characterization, Ben specializes in mass spectrometry and related tools, particularly peptide mapping, for determining the structure of client proteins, monitoring critical quality attributes, and investigating unknown impurities. His approach emphasizes delivering understanding and actionable insight rather than raw data, ensuring clients have the information they need to make informed decisions about their biotherapeutic products.

Ben's expertise spans identity confirmation, PTM profiling, sequence variant detection, and impurity characterization across multiple modalities.

Flexible, Knowledgeable, and Proven


About KBI Biopharma

KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of our 1400+ customer partners, we work closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, we deliver robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial. Recognized for quality manufacturing, we help clients advance drug candidates into the clinic and beyond. 

Science Driven. Customer Focused.